Salarius Pharmaceuticals, Inc. (SLRX) Revenue History
Annual and quarterly revenue from 2015 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SLRX Revenue Growth
Revenue Breakdown (FY 2020)
SLRX's revenue distribution by segment and geography for fiscal year 2020
By Product/Segment
SLRX Revenue Analysis (2015–2024)
As of May 8, 2026, Salarius Pharmaceuticals, Inc. (SLRX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, SLRX's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $5.2 million in 2020.
Revenue diversification analysis shows SLRX's business is primarily driven by Grant, Castration-Resistant Prostate Study (100%). With over half of revenue concentrated in Grant, Castration-Resistant Prostate Study, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including KROS (+6775.0% YoY), TPVG, and AGEN (+10.4% YoY). Compare SLRX vs KROS →
SLRX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SLRXCurrent | $0 | - | - | - | |
 KROS | $244M | +6775.0% | - | 28.9% | |
 TPVG | $97M | - | - | 77.9% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% |
SLRX Historical Revenue Data (2015–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $0 | - | $-5,734,316 | - |
| 2023 | $0 | - | $0 | - | $-12,894,944 | - |
| 2022 | $0 | - | $0 | - | $-31,841,140 | - |
| 2021 | $0 | -100.0% | $0 | - | $-12,812,931 | - |
| 2020 | $5.2M | +51.0% | $5.2M | 100.0% | $-7,786,345 | -148.8% |
| 2019 | $3.5M | +313.4% | $3.5M | 100.0% | $-8,265,077 | -238.5% |
| 2018 | $838K | -34.2% | $407K | 48.6% | $-22,074,223 | -2633.7% |
| 2017 | $1.3M | +26.1% | $768K | 60.3% | $-34,725,626 | -2724.6% |
| 2016 | $1.0M | - | $348K | 34.4% | $-39,886,232 | -3946.5% |
| 2015 | $0 | - | $-49,881 | - | $-29,213,000 | - |
See SLRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SLRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSLRX — Frequently Asked Questions
Quick answers to the most common questions about buying SLRX stock.
Is SLRX's revenue growth accelerating or slowing?
SLRX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is SLRX's long-term revenue growth rate?
Salarius Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is SLRX's revenue distributed by segment?
SLRX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2015-2024 are available for download. Segment mix reveals concentration and diversification trends.